These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

850 related articles for article (PubMed ID: 23171357)

  • 21. "Triple hit" lymphomas: A retrospective cytology case series of an uncommon high grade B-cell malignancy with C-MYC, BCL-2 and BCL-6 rearrangements.
    Eldessouki T; Hanley K; Hamadeh F; Oshilaja OO; Sturgis CD
    Diagn Cytopathol; 2018 Sep; 46(9):807-811. PubMed ID: 30043475
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aggressive B-cell lymphomas with translocations involving BCL6 and MYC have distinct clinical-pathologic characteristics.
    Turakhia SK; Hill BT; Dufresne SD; Nakashima MO; Cotta CV
    Am J Clin Pathol; 2014 Sep; 142(3):339-46. PubMed ID: 25125624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytomorphologic findings of B-cell lymphomas with concurrent IGH/BCL2 and MYC rearrangements (dual-translocation lymphomas).
    da Cunha Santos G; Ko HM; Saieg MA; Boerner SL; Lai SW; Bailey D; Geddie WR
    Cancer Cytopathol; 2011 Aug; 119(4):254-62. PubMed ID: 21560251
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MYC rearranged B-cell neoplasms: Impact of genetics on classification.
    Haberl S; Haferlach T; Stengel A; Jeromin S; Kern W; Haferlach C
    Cancer Genet; 2016 Oct; 209(10):431-439. PubMed ID: 27810071
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Translocations involving the immunoglobulin heavy chain gene locus predict better survival in gastric diffuse large B-cell lymphoma.
    Nakamura S; Ye H; Bacon CM; Goatly A; Liu H; Kerr L; Banham AH; Streubel B; Yao T; Tsuneyoshi M; Savio A; Takeshita M; Dartigues P; Ruskoné-Fourmestraux A; Matsumoto T; Iida M; Du MQ
    Clin Cancer Res; 2008 May; 14(10):3002-10. PubMed ID: 18445693
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The distinction between Burkitt lymphoma and diffuse large B-Cell lymphoma with c-myc rearrangement.
    Nakamura N; Nakamine H; Tamaru J; Nakamura S; Yoshino T; Ohshima K; Abe M
    Mod Pathol; 2002 Jul; 15(7):771-6. PubMed ID: 12118116
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnosis of 'double hit' diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC.
    Swerdlow SH
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):90-9. PubMed ID: 25696840
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Primary ocular adnexal lymphoproliferative lesions: clinicopathologic features and genetic alterations].
    Dong LN; Liu HG; Jin HS; Ye HT; Gao ZF; Zhou XG; Dong GH; Zhang DD; Gong LP
    Zhonghua Bing Li Xue Za Zhi; 2008 Dec; 37(12):809-14. PubMed ID: 19159526
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Fluorescence in situ hybridization in the diagnosis of aggressive B-cell lymphomas].
    Gerhard-Hartmann E; Rosenwald A
    Pathologe; 2020 Nov; 41(6):574-581. PubMed ID: 32909092
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MYC, BCL2, and BCL6 rearrangements in primary central nervous system lymphoma of large B cell type.
    Nosrati A; Monabati A; Sadeghipour A; Radmanesh F; Safaei A; Movahedinia S
    Ann Hematol; 2019 Jan; 98(1):169-173. PubMed ID: 30306208
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type.
    Yoon SO; Jeon YK; Paik JH; Kim WY; Kim YA; Kim JE; Kim CW
    Histopathology; 2008 Aug; 53(2):205-17. PubMed ID: 18752503
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytopathology of "double-hit" non-Hodgkin lymphoma.
    Elkins CT; Wakely PE
    Cancer Cytopathol; 2011 Aug; 119(4):263-71. PubMed ID: 21560252
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Burkitt lymphoma (BL): reclassification of 39 lymphomas diagnosed as BL or Burkitt-like lymphoma in the past based on immunohistochemistry and fluorescence in situ hybridization.
    Kodet R; Mrhalová M; Stejskalová E; Kabícková E
    Cesk Patol; 2011 Jul; 47(3):106-14. PubMed ID: 21887927
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Altered subcellular localization of c-Myc protein identifies aggressive B-cell lymphomas harboring a c-MYC translocation.
    Ruzinova MB; Caron T; Rodig SJ
    Am J Surg Pathol; 2010 Jun; 34(6):882-91. PubMed ID: 20442643
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma.
    Huang S; Nong L; Wang W; Liang L; Zheng Y; Liu J; Li D; Li X; Zhang B; Li T
    Diagn Pathol; 2019 Jul; 14(1):81. PubMed ID: 31315646
    [TBL] [Abstract][Full Text] [Related]  

  • 36. "Double-Hit" mature B-cell lymphomas show a common immunophenotype by flow cytometry that includes decreased CD20 expression.
    Wu D; Wood BL; Dorer R; Fromm JR
    Am J Clin Pathol; 2010 Aug; 134(2):258-65. PubMed ID: 20660329
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Double-hit lymphomas: clinical, morphological, immunohistochemical and cytogenetic study in a series of Brazilian patients with high-grade non-Hodgkin lymphoma.
    Oliveira CC; Maciel-Guerra H; Kucko L; Hirama EJ; Brilhante AD; Quevedo FC; da Cunha IW; Soares FA; Niero-Melo L; Dos Reis PP; Domingues MA
    Diagn Pathol; 2017 Jan; 12(1):3. PubMed ID: 28061782
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aggressive B cell Lymphoma: Optimal Therapy for MYC-positive, Double-Hit, and Triple-Hit DLBCL.
    Dunleavy K
    Curr Treat Options Oncol; 2015 Dec; 16(12):58. PubMed ID: 26634708
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MYC/BCL2/BCL6 triple hit lymphoma: a study of 40 patients with a comparison to MYC/BCL2 and MYC/BCL6 double hit lymphomas.
    Huang W; Medeiros LJ; Lin P; Wang W; Tang G; Khoury J; Konoplev S; Yin CC; Xu J; Oki Y; Li S
    Mod Pathol; 2018 Sep; 31(9):1470-1478. PubMed ID: 29785017
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
    Green TM; Young KH; Visco C; Xu-Monette ZY; Orazi A; Go RS; Nielsen O; Gadeberg OV; Mourits-Andersen T; Frederiksen M; Pedersen LM; Møller MB
    J Clin Oncol; 2012 Oct; 30(28):3460-7. PubMed ID: 22665537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.